Neuromuscular Disease
RSSArticles
-
Tolebrutinib May Slow Disability Progression in Patients with SPMS
A recent prospective study showed that tolebrutinib slows disability progression in patients with nonrelapsing secondary progressive multiple sclerosis (SPMS). There were some safety concerns, especially hepatotoxicity. A lack of demonstrated effect on some functional outcomes warrants careful consideration and continuing study.
-
Nipocalimab-aahu Injection (Imaavy)
The U.S. Food and Drug Administration has approved a neonatal Fc-receptor (FcRn) blocker for the treatment of generalized myasthenia gravis. Nipocalimab-aahu is a recombinant human immunoglobulin G1 lambda monoclonal antibody directed at FcRn with high affinity and selectivity.
-
Long-Term Efficacy of Ocrelizumab as First-Line Treatment for Relapsing-Remitting Multiple Sclerosis
Nine-year follow-up data from open-label extension of the Phase III clinical trials of ocrelizumab show that, although the efficacy of ocrelizumab was maintained throughout the duration of the study, patients who were treated with ocrelizumab from the beginning of the Phase III trials did better than the patients who were on subcutaneous (SC) interferon β-1a initially and were switched to ocrelizumab at the onset of the open-label extension period.
-
Efgartigimod for Seronegative Myasthenia Gravis
In an uncontrolled, open-label series of patients with myasthenia gravis, double antibody-negative patients responded to immunosuppressive therapies in a similar manner as do those with antibodies to acetylcholine receptors (AChR) or muscle-specific tyrosine kinase. However, when treating myasthenia patients with a specific agent (efgartigimod) that blocks AChR antibodies at the level of endothelial cells, double antibody-negative patients do not respond as well.
-
Antidepressants for Chronic Pain: Do They Work?
Antidepressant medications have been widely used for treating a variety of chronic pain disorders, but strong evidence to support their efficacy is lacking. Some patients may respond, but available data do not help us determine which agents may be helpful in a specific type of chronic pain condition.
-
Carpal Tunnel Syndrome in the Extreme Elderly
Carpal tunnel syndrome (CTS), when seen in the very elderly, is usually severe and is not reliably diagnosed by ultrasound. Nerve conduction studies and electromyography are the most sensitive and specific tests to make accurate diagnosis of CTS.
-
How Common Are Neuromuscular Disorders?
Synopsis: Although many specific neuromuscular disorders are rare, in aggregate, these all add up to a large number, roughly twice as common as multiple sclerosis, and about the same prevalence as Parkinson’s disease.
-
When Is it Best to Evaluate the Results of a CSF Tap Test?
The tap test has variable results as a tool to assess patients with a presumed diagnosis of normal pressure hydrocephalus. -
Rituximab May Be Effective for Refractory Myasthenia Gravis
In a restrospective review, rituximab appeared beneficial for patients with medication-resistant myasthenia gravis. -
Pharmacology Watch
New recommendations for HPV vaccine; guidelines for treatment of essential tremor; updates on smoking cessation drugs; and FDA actions.